<DOC>
	<DOCNO>NCT01749306</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ABH001 treatment patient epidermolysis bullosa wound heal . It hypothesize ABH001 may initiate continue wound heal patient epidermolysis bullosa .</brief_summary>
	<brief_title>A Study Efficacy Safety ABH001 Treatment Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>1 . The subject legal guardian must read , understood sign Institutional Review Board/Ethics Committee ( IRB/EC ) approve Informed Consent Assent Form must able willing follow study procedure instruction 2 . Male female subject . 3 . Stable nutritional status . 4 . Subjects confirm diagnosis generalize Epidermolysis Bullosa ( EB ) 5 . Cutaneous wound meet follow criterion : 1 . Anatomical location : arm , leg , thorax , back waistline neck . 2 . Documented age ( duration ) wound ( ) . 3 . One wound capable potentially meet follow wound selection criterion end observation period : . Two clinically noninfected cutaneous wound clinically meaningful change wound size observation period . ii . Two match wound . 6 . Negative urine pregnancy test woman childbearing potential . 7 . Female subject childbearing potential male subject procreative capacity must agree use effective method contraception . 1 . Pregnant nursing woman . 2 . Diagnosis nongenetic generalize EB . 3 . Localized , active clinical infection study wound . 4 . Diseases condition could interfere assessment safety efficacy study treatment compliance subject study visits/procedures . 5 . Known allergy bovine product . 6 . Known allergy silver product . 7 . Systemic infection time enrolment study . 8 . Currently receive receive oral steroid therapy within previous 4 week . 9 . Taking , participate clinical study involve gene therapy , stem cell therapy , recombinant DNA/protein therapy . 10 . Received ABH001 , biologic cell therapy treatment EB study wound site within previous 3 month . 11 . Hypersensitivity therapeutic agent . 12 . History malignant skin disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>epidermolysis bullosa , chronic wound , wound healing , dermal repair , fibroblast , Dermagraft</keyword>
</DOC>